WASHINGTON, D.C., April 30, 2026
AstraZeneca announced that the U.S. Food and Drug Administration’s Oncologic Drugs Advisory Committee (ODAC) has recommended its targeted therapy TRUQAP® (capivasertib) in combination with abiraterone and androgen deprivation therapy (ADT) for patients with PTEN-deficient metastatic hormone-sensitive prostate cancer (mHSPC). The committee voted 7 to 1 (with one abstention), concluding that the combination demonstrates a favorable benefit-risk profile, marking a significant step toward expanding treatment options in this aggressive cancer subtype.
Breakthrough Targeted Therapy Addresses High-Risk Subtype
The recommendation is based on results from the CAPItello-281 Phase III trial, which is the first pivotal study to prospectively define and target PTEN-deficient mHSPC, a subgroup associated with poor prognosis and rapid disease progression. Approximately one in four patients with metastatic hormone-sensitive prostate cancer harbor PTEN deficiency, making this a clinically important population with limited treatment options.
TRUQAP, an AKT inhibitor, directly targets the PI3K/AKT signaling pathway, a key driver of tumor growth when PTEN function is lost. By combining TRUQAP with standard hormonal therapies, AstraZeneca aims to delay disease progression and extend treatment response duration, addressing a major unmet medical need in prostate oncology
Strong Clinical Data Demonstrates Disease Control Benefits
Advertisement
In the CAPItello-281 trial, the TRUQAP combination showed a 19% reduction in the risk of disease progression or death, along with a clinically meaningful improvement in median radiographic progression-free survival (rPFS). Patients receiving TRUQAP achieved 33.2 months rPFS compared to 25.7 months in the control group, representing a significant extension in disease control.
Additional secondary endpoints reinforced these findings, including longer time to castration resistance (29.5 vs. 22.0 months) and delayed prostate-specific antigen (PSA) progression. Early overall survival data also numerically favored the TRUQAP arm, although it remains immature and will continue to be evaluated as the trial progresses. These results highlight the therapy’s ability to slow tumor growth and delay progression, which is critical in improving long-term outcomes for patients.
Safety Profile and Risk Considerations
While efficacy outcomes are promising, the safety profile reflects the complexity of combining targeted therapy with hormonal treatment. Grade 3 or higher adverse events occurred in 67% of patients receiving TRUQAP, compared to 40.4% in the control arm. The most common severe side effects included rash, hyperglycemia, hypokalemia, diarrhea, hypertension, and anemia.
Notably, hyperglycemia remains a key risk, requiring close monitoring and potential intervention, including glucose-lowering therapies. Despite these risks, the advisory committee determined that the clinical benefits outweigh the safety concerns, particularly given the lack of effective targeted treatments for this patient population.
Regulatory Pathway and Market Implications
The ODAC recommendation is a critical milestone, but it is not binding. The FDA will consider the committee’s input as it reviews AstraZeneca’s supplemental New Drug Application (sNDA). A final regulatory decision is expected later in 2026. In parallel, a regulatory submission is also under review in Europe, signaling a global strategy to expand TRUQAP’s use beyond breast cancer, where it is already approved in multiple regions. If approved, this would position TRUQAP as the first and only targeted therapy specifically indicated for PTEN-deficient mHSPC, potentially reshaping the treatment landscape.
Expanding Role of Precision Oncology
This development underscores the growing importance of precision medicine in oncology, where treatments are tailored based on specific genetic alterations such as PTEN loss. By targeting the molecular drivers of cancer, therapies like TRUQAP are moving beyond traditional one-size-fits-all approaches toward more personalized and effective treatment strategies. AstraZeneca’s broader oncology pipeline continues to focus on biomarker-driven therapies, aiming to improve survival outcomes and quality of life for patients with difficult-to-treat cancers.
The ODAC’s strong support for TRUQAP highlights both the clinical urgency and scientific progress in treating aggressive prostate cancer. If approved, this therapy could provide a new standard of care for patients with PTEN-deficient disease, offering improved disease control and a much-needed targeted treatment option.
Source: AstraZeneca press release
